A detailed history of Advisor Group Holdings, Inc. transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 381 shares of RCKT stock, worth $3,992. This represents 0.0% of its overall portfolio holdings.

Number of Shares
381
Previous 395 3.54%
Holding current value
$3,992
Previous $8,000 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$17.6 - $25.88 $246 - $362
-14 Reduced 3.54%
381 $7,000
Q2 2024

Aug 13, 2024

BUY
$20.66 - $26.72 $2,871 - $3,714
139 Added 54.3%
395 $8,000
Q1 2024

May 10, 2024

SELL
$26.16 - $30.74 $59,540 - $69,964
-2,276 Reduced 89.89%
256 $6,000
Q4 2023

Feb 12, 2024

SELL
$16.78 - $31.94 $3,708 - $7,058
-221 Reduced 8.03%
2,532 $75,000
Q3 2023

Nov 13, 2023

BUY
$15.07 - $24.05 $7,595 - $12,121
504 Added 22.41%
2,753 $56,000
Q2 2023

Aug 10, 2023

BUY
$16.59 - $23.6 $4,147 - $5,900
250 Added 12.51%
2,249 $44,000
Q1 2023

May 12, 2023

BUY
$15.79 - $22.6 $1,200 - $1,717
76 Added 3.95%
1,999 $34,000
Q4 2022

Feb 10, 2023

BUY
$15.5 - $22.76 $26,706 - $39,215
1,723 Added 861.5%
1,923 $37,000
Q3 2022

Nov 14, 2022

SELL
$12.37 - $18.41 $556 - $828
-45 Reduced 18.37%
200 $3,000
Q2 2022

Aug 10, 2022

SELL
$7.96 - $16.64 $334 - $698
-42 Reduced 14.63%
245 $4,000
Q1 2022

May 04, 2022

BUY
$13.16 - $23.68 $144 - $260
11 Added 3.99%
287 $4,000
Q2 2021

Aug 02, 2021

SELL
$39.41 - $47.25 $3,862 - $4,630
-98 Reduced 26.2%
276 $12,000
Q1 2021

May 13, 2021

BUY
$43.34 - $65.91 $6,197 - $9,425
143 Added 61.9%
374 $16,000
Q4 2020

Feb 10, 2021

BUY
$23.3 - $59.57 $4,660 - $11,914
200 Added 645.16%
231 $13,000
Q1 2020

May 18, 2020

BUY
$9.71 - $25.11 $301 - $778
31 New
31 $0

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $793M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.